Combination therapy
The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.
1. A method for achieving a reduction in the dose of a GLP-1 receptor agonist required for reducing and maintaining body weight and/or body fat in an overweight or obesity patient with or without diabetes, said method comprising administering the GLP-1 receptor agonist in combination with linagliptin to the patient, wherein said administration is sequential administration of the GLP-1 receptor agonist in an amount effective to reduce body weight and/or body fat followed by linagliptin in an amount effective to maintain the reduced body weight and/or body fat.
2. The method according to claim 1 , wherein the GLP-1 receptor agonist is selected from the group consisting of exenatide, exenatide LAR, liraglutide, taspoglutide, semaglutide, albiglutide, lixisenatide and dulaglutide.
3. The method according to claim 1 , wherein the GLP-1 receptor agonist and linagliptin are present in separate dosage forms.
4. The method of claim 1 , wherein the GLP-1 receptor agonist is exenatide.